VIVUS Inc. (VVUS)

3.27
NASDAQ : Health Technology
Prev Close 3.36
Day Low/High 3.26 / 3.36
52 Wk Low/High 2.15 / 9.10
Avg Volume 48.40K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 35.74M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
January 10th Options Now Available For Vivus (VVUS)

January 10th Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the January 10th expiration.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

Looking at What Didn't Work

Looking at What Didn't Work

Time to examine a couple that didn't pan out.

Interesting VVUS Put And Call Options For December 27th

Interesting VVUS Put And Call Options For December 27th

Investors in Vivus, Inc. saw new options begin trading today, for the December 27th expiration.

Vivus (VVUS) Showing Signs Of Perilous Reversal Today

Vivus (VVUS) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Vivus (VVUS) as a "perilous reversal" (up big yesterday but down big today) candidate

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to trade higher from current levels.

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma

Biotech Stock Mailbag: Enteromedics, ARCA Biopharma, Keryx Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

[video] A Chart You Should See: Investors Put Greater Weight Behind Orexigen Than Arena, Vivus

[video] A Chart You Should See: Investors Put Greater Weight Behind Orexigen Than Arena, Vivus

Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.

[video] Orexigen Weight-Loss Pill Passes Safety Hurdle

[video] Orexigen Weight-Loss Pill Passes Safety Hurdle

Contrave will be resubmitted for FDA approval "within a few weeks," Orexigen said.

VIVUS Announces Support For New Obesity Treatment Guidance Urging Active Involvement From Healthcare Providers

VIVUS Announces Support For New Obesity Treatment Guidance Urging Active Involvement From Healthcare Providers

New Guidelines and Publication Encourage Physicians and Patients to Work Together to Find the Right Treatment Plan, Which May Include Medication

Kyle Bass Gets In On Herbalife, Microsoft, J.C. Penney

Kyle Bass Gets In On Herbalife, Microsoft, J.C. Penney

Kyle Bass’ Hayman Capital got in on a few embattled and controversial stocks during the September quarter. His latest 13F filing shows that his new stocks for the September quarter included Herb...

November 22nd Options Now Available For Vivus (VVUS)

November 22nd Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the November 22nd expiration.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

Insider Trading Alert - MOS, VVUS, XRAY, PSX And IVZ Traded By Insiders

Insider Trading Alert - MOS, VVUS, XRAY, PSX And IVZ Traded By Insiders

Stocks with insider trader activity include MOS, VVUS, XRAY, PSX and IVZ

Top Insider Trades: AGCO VVUS INWK ACRX

Top Insider Trades: AGCO VVUS INWK ACRX

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines

Arena Expands Marketing Of Obesity Drug To Help Shrink Waistlines

Chris Lau, Kapitall: ArenaA and a partner will expand marketing efforts for a weight loss drug, but is there more room [...]

Jim Cramer's 6 Stocks in 60 Seconds: VVUS CVS BWLD HAIN PXD ECANE (Update 1)

Jim Cramer's 6 Stocks in 60 Seconds: VVUS CVS BWLD HAIN PXD ECANE (Update 1)

Cramer says to be careful with Vivus but he sees CVS going higher.

November 8th Options Now Available For Vivus (VVUS)

November 8th Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the November 8th expiration.

Newly Published Study Finds Qsymia Achieves Greater Weight Loss At Lower Doses Than Either Of Its Components As Monotherapy

Newly Published Study Finds Qsymia Achieves Greater Weight Loss At Lower Doses Than Either Of Its Components As Monotherapy

Once-Daily Extended-Release Qsymia Achieved 10% Weight Loss, Was Well Tolerated and Improved Blood Pressure

November 1st Options Now Available For Vivus (VVUS)

November 1st Options Now Available For Vivus (VVUS)

Investors in Vivus, Inc. saw new options become available today, for the November 1st expiration.

Trade-Ideas: Vivus (VVUS) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Vivus (VVUS) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Vivus (VVUS) as a "perilous reversal" (up big yesterday but down big today) candidate

Stock Futures Rise as Obama Taps Yellen as Fed Chief

Stock Futures Rise as Obama Taps Yellen as Fed Chief

Investors brace for a longer period of easy monetary policy as Janet Yellen is chosen as the next Fed chief.

TheStreet Quant Rating: D (Sell)